Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026)
Compass Therapeutics (CMPX) posted Income from Continuing Operations of 53211000.0 for Q1 2026, down 194.24% sequentially from 18084000.0 in Q4 2025, and down 219.91% YoY from 44374959.29 in Q1 2025.
Powered by 
Analysis
Compass Therapeutics (CMPX) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Income from Continuing Operations for 9 years, with the latest figure at 53211000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 219.91% year-over-year to 53211000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 126781000.0 (down 111.23% YoY) and the FY2025 annual result came in at 151969000.0, down 31.06% from the prior year.
- Income from Continuing Operations slipped to 53211000.0 in Q1 2026 per CMPX's latest filing, from 18084000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 7162000.0 in Q1 2022 and troughed at 53211000.0 in Q1 2026.
- A 5-year average of 16429882.35 and a median of 13076000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations rose 16.79% in 2023, then tumbled 219.91% in 2026.
- Over 5 years, Income from Continuing Operations stood at 11594000.0 in 2022, then dropped by 15.71% to 13415000.0 in 2023, then fell by 25.61% to 16850000.0 in 2024, then dropped by 7.32% to 18084000.0 in 2025, then plunged by 194.24% to 53211000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 53211000.0, 18084000.0, and 27374000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Compass Therapeutics | 442.72 Mn | 442.72 Mn | - | -27.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.07 Mn |
| Mar 31, 2026 | -20.74 Mn |
| Dec 31, 2025 | -17.98 Mn |
| Sep 30, 2025 | -15.75 Mn |
| Jun 30, 2025 | -21.05 Mn |
| Mar 31, 2025 | -16.63 Mn |
| Dec 31, 2024 | -16.85 Mn |
| Sep 30, 2024 | -11.66 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.79 Mn |
| Dec 31, 2023 | -13.42 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -7.84 Mn |
| Dec 31, 2022 | -11.59 Mn |
| Sep 30, 2022 | -11.98 Mn |
| Jun 30, 2022 | -8.49 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.98 Mn |
| Sep 30, 2021 | -5.98 Mn |